samedan logo
 
 
spacer
home > white papers > High Potency Drugs – from Molecule to Market - PCI Pharma Services
WHITE PAPERS
logo_PCI_PharmaL.jpg

PCI Pharma Services

phone +44 (0)1495 713 633
email sales@pciservices.com
web http://www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG

High Potency Drugs – from Molecule to Market

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials

Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
More info >>


White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement